Bundibugyo Ebola Pseudovirus
Comprehensive Neutralization Assay Solutions for Advancing Sudan ebolavirus Research
Bundibugyo Ebola Pseudovirus
Bundibugyo Ebola pseudoviruses provide a safe, versatile, and highly relevant platform for studying viral entry and evaluating medical countermeasures without the need for high-containment facilities. By incorporating the Bundibugyo ebolavirus glycoprotein (GP) onto a replication-deficient viral backbone, these pseudoviruses faithfully mimic the entry process of the authentic virus while enabling work in standard BSL-2 laboratories.
Pseudocvirus are valuable tools for measuring neutralizing antibody responses, screening antiviral compounds, and assessing vaccine-induced immunity against this emerging Ebola species. Given the limited availability of clinical samples and the rarity of Bundibugyo outbreaks, pseudovirus-based assays offer a practical and scalable solution for accelerating vaccine development, therapeutic antibody discovery, and preparedness efforts against future outbreaks.
Production service
At IVANO Bioscience, we understand that emerging viral threats often require tailored research solutions. Through our custom development services, we partner with clients to design and produce pseudoviruses that meet their specific research needs.
Whether supporting vaccine developers, therapeutic antibody programs, antiviral screening campaigns, or academic research initiatives, our team can rapidly generate customized Bundibugyo Ebola pseudoviruses and assay platforms optimized for target variants, experimental workflows, and regulatory requirements.
By combining scientific expertise with flexible manufacturing capabilities, IVANO Bioscience helps accelerate preclinical research and enables faster evaluation of promising countermeasures against current and future Ebola virus outbreaks.
Bundibugyo Ebola Pseudovirus
Bundibugyo ebolavirus (BDBV) is a rare species of Ebola virus first identified during an outbreak in Uganda’s Bundibugyo District in 2007. Unlike the more common Zaire ebolavirus, Bundibugyo virus has been responsible for only a few documented outbreaks, including a significant epidemic in the Democratic Republic of the Congo (DRC) in 2012. Despite its rarity, the virus can cause severe Ebola virus disease with high mortality rates.
Today, Bundibugyo ebolavirus is once again drawing global attention as it drives a major outbreak affecting the DRC and neighboring Uganda, highlighting the ongoing need for effective surveillance, diagnostics, and countermeasure development.
